Skip to main content
Fig. 4 | Clinical Epigenetics

Fig. 4

From: The predictive value of BTG1 for the response of newly diagnosed acute myeloid leukemia to decitabine

Fig. 4

The methylation density of 3′UTR and gene expression of BTG1 in AML patients. A The methylation density of BTG1 was decreased in patients receiving decitabine + IA regimen. B The methylation density of BTG1 was increased in patients receiving IA regimen. The change of methylation density in patients with CR (C) and in patients with non-CR (D) in treatment with decitabine + IA regimen (the black beads presented methylated sites, the white beads presented unmethylated sites). E The change of BTG1 expression in patients receiving decitabine + IA regimen. F The change of BTG1 expression in patients receiving IA regimen. The change of BTG1 expression in patients with CR (G) and in patients with non-CR (H) in treatment with decitabine + IA regimen. I The negative association of the methylation density and gene expression of BTG1. J The association between BTG1 expression in bone marrow and that in peripheral blood samples

Back to article page

Clinical Epigenetics

ISSN: 1868-7083

Contact us